Rachel H. Kravitz
Directeur Technique/Scientifique/R&D chez NeoClone Biotechnology International LLC
Profil
Rachel H.
Kravitz is currently working as a Research Director at NeoClone Biotechnology International LLC since 2003.
She completed her undergraduate degree from Tufts University in 1989 and received her doctorate degree from the University of California, Davis in 1998.
Postes actifs de Rachel H. Kravitz
| Sociétés | Poste | Début |
|---|---|---|
NeoClone Biotechnology International LLC
 NeoClone Biotechnology International LLC BiotechnologyHealth Technology NeoClone Biotechnology International LLC engages in the production and supply of monoclonal antibody products. The firm offers antibodies to bacterial transcription proteins, RNA polymerase II, bacterial toxins, eukaryotic transcription proteins, neural proteins, cancer proteins, cardiac biomarkers, and interferon gamma, as well as offers cancer antibodies and Softag products. It provides contract monoclonal antibodies for companies and individual researchers, as well as for university and industry researchers. The company was founded in 1999 by Mark Jackson, Donal Kaehler, David Largaspaeda and Deven McGlenn and is headquartered in Madison, WI. | Directeur Technique/Scientifique/R&D | 01/01/2003 |
Formation de Rachel H. Kravitz
| Tufts University | Undergraduate Degree |
| University of California, Davis | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
NeoClone Biotechnology International LLC
NeoClone Biotechnology International LLC BiotechnologyHealth Technology NeoClone Biotechnology International LLC engages in the production and supply of monoclonal antibody products. The firm offers antibodies to bacterial transcription proteins, RNA polymerase II, bacterial toxins, eukaryotic transcription proteins, neural proteins, cancer proteins, cardiac biomarkers, and interferon gamma, as well as offers cancer antibodies and Softag products. It provides contract monoclonal antibodies for companies and individual researchers, as well as for university and industry researchers. The company was founded in 1999 by Mark Jackson, Donal Kaehler, David Largaspaeda and Deven McGlenn and is headquartered in Madison, WI. | Health Technology |
